Skip to main content

Search

Site

Search results

12 SEARCH RESULTS FOR

Esketamine

Not finding what you're looking for? Visit Janssen in your country.
PAGE 1 OF 2

Pages

Sep 21, 2018 United States Study is one of five submitted to U.S. FDA by Janssen as part of its new drug application for esketamine nasal spray for treatment-resistant depression   TITUSVILLE, N.J., Sept. 21, 2018  -- The Janssen Pharmaceutical Companies ...

May 31, 2018 United States A separate Phase 3 study provides evidence that esketamine was generally well tolerated with no new safety signals with up to 52 weeks of dosing for patients with treatment-resistant depression TITUSVILLE, N.J., May 31, 2018  -- ...

Oct 10, 2018 Belgium Data from five pivotal Phase 3 studies submitted as the basis for Marketing Authorisation Application for esketamine nasal spray   BEERSE, Belgium-- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the ...

Jun 19, 2018 Belgium One long-term study provides evidence that esketamine delayed time to relapse A second study shows esketamine was generally well tolerated with no new safety signals   BEERSE, Belgium-- The Janssen Pharmaceutical Companies of Johnson ...

May 05, 2018 United States Study in adults with treatment-resistant depression marks the first time an antidepressant has achieved superiority in a clinical trial for major depressive disorder that included a newly initiated oral antidepressant in both ...

Apr 16, 2018 United States   Media Contact: Greg Panico 609-730-3061 (office) 908-240-2011 (mobile) Investor Contacts: Joseph J. Wolk 732-524-1142 (office) Lesley Fishman 732-524-3922 (office) If approved by the FDA, esketamine nasal spray would be the ...

Dec 28, 2017 United States TITUSVILLE, N.J., Dec. 28, 2017 /PRNewswire/-- Janssen Research & Development, LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced that data from a Phase 2 clinical study of intranasal ...

Feb 12, 2019 United States If approved, SPRAVATO™ will offer the first new mechanism of action in 30 years to treat this debilitating disease, continuing Janssen's 60-plus-year history and commitment to research that make a difference for people ...

Sep 04, 2018 United States If approved, esketamine nasal spray would provide the first new mechanism of action in 30 years to treat this debilitating mental illness 1, 2   TITUSVILLE, N.J., Sept. 4, 2018  -- The Janssen Pharmaceutical Companies of Johnson ...

May 21, 2019 United States NEW ORLEANS, May 21, 2019  -- The Janssen Pharmaceutical Companies of Johnson & Johnson presented a   new cost-efficiency analysis at the International Society for Pharmacoeconomics and Outcomes Research Annual Meeting ...

12 SEARCH RESULTS FOR

Esketamine

Not finding what you're looking for? Visit Janssen in your country.
PAGE 1 OF 2

Pages